Ultragenyx to spin off company to develop ‘high risk, high return’ gene therapy for Alzheimer’s disease
Ultragenyx plans to spin off a company dedicated to developing a novel gene therapy for Alzheimer’s disease that makes use of a lysosomal enzyme, the …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.